News | January 28, 2022
Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Biocon has reported consolidated financial results for the period ended December 31, 2021
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
